The meaningful increase in today’s price appears to be due to the reported approval of Gilead’s CAR-T drug Yescarta in China. On another matter, CEO Jerry Shelton (for whom I have great respect) has said that the company’s goal is to reach $650 million of sales in 2025 through organic growth. Acquisitions could increase this. […]
Welcome to SmithonStocks (SOS), home to in-depth financial analysis and research reports with a focus on emerging biotechnology companies.
You now must be a subscriber in order to gain full access to new and featured reports. Please click the "Subscribe" button to register for a SoS subscription. If you are already have a SoS subscription account please log in now.
As always, all blog posts and old reports do not require a subscription to read.
Thank you for visiting SmithonStocks.com.